TICKERNERD
Menu
NTRBNTRBHealthcare · Biotechnology

NTRB Stock Forecast: Nutriband, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.75
+24.51% on the day

The 1 Wall Street analysts covering Nutriband, Inc. hold a median 12-month price target of $15 — +215.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$56.7M
Ticker Nerd rank
19 / 100
Median analyst target
$15
Analysts covering
1
Total return, dividends reinvested
1W
+43.9%
1M
+54.2%
YTD
+4.6%
1Y
−24.7%
From 52W high
−44.1%
From 52W low
+69.0%
$2.81
$8.50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NTRB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nutriband, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
88
Size
81
Issuance
50
Volatility
33
Revisions
25
Growth
24
Value
15
Momentum
12
Quality
8

Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NTRB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTRB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00$16.00Oct 25Jan 26Apr 26Jul 26NTRBHigh $15Median $15Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $15Median $15High $15

The green dot is the last close — the median target sits +215.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Jan 2025Noble Capital MarketsInitiatesOutperform$13
26 July 2022Small Cap Consumer ResearchMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTRB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NTRB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Nutriband, Inc. (NTRB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.8×

Cheaper than 84% of US stocks

Price / sales
31.5×

Cheaper than 8% of US stocks

Price / book
9.5×

Cheaper than 12% of US stocks

EV / EBITDA
−6.6×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
−35.1%

Higher than 7% of US stocks

Earnings growth (YoY)
−35.1%

Higher than 14% of US stocks

Gross margin
45.4%

Higher than 57% of US stocks

Operating margin
−289.4%

Higher than 9% of US stocks

Net margin
27.8%

Higher than 87% of US stocks

Returns & dividend
Return on equity
−145.7%

Higher than 9% of US stocks

Return on assets
−78.2%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NTRB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NTRBNutriband, Inc.$56.7M
19
HRTXHeron Therapeutics, Inc.$58.3M
44
APLMApollomics, Inc.$53.4M
16
RNXTRenovoRx, Inc.$59.5M
37
INKTMiNK Therapeutics, Inc.$60.6M
57
XLOXilio Therapeutics, Inc.$60.7M
72
TILInstil Bio, Inc.$51.4M
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nutriband, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NTRB news & analysis

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

GlobeNewsWire · 13 Aug 2026neutral

Nutriband announced that its CEO and Co-Founder, Gareth Sheridan, will present at the 2026 Georgia Life Sciences Summit on Aug 26 as part of the CEO spotlight event. The announcement was made by the company on Aug 13, 2026.

Why it matters — The CEO's scheduled appearance at the summit provides NTRB watchers with visibility into the company's leadership engagement within the life sciences sector.

FAQ

Frequently asked questions about NTRB stock

What is the NTRB stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Nutriband, Inc. have a median 12-month price target of $15, with estimates ranging from $15 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTRB stock a buy right now?

Of the 1 analysts covering Nutriband, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nutriband, Inc. 19 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTRB?

As at 22 Aug 2026, Nutriband, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).

Will NTRB stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +215.8% from the last close, and Ticker Nerd's factor model ranks Nutriband, Inc. 19 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTRB stock forecast for 2030?

No analyst covering Nutriband, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $15 over the next 12 months.

How has NTRB stock performed over the past year?

Nutriband, Inc. returned -24.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nutriband, Inc. do?

Nutriband Inc. is a pharmaceutical and healthcare company specializing in the development and commercialization of transdermal products and technologies.

What is the latest news on NTRB?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight". Nutriband announced that its CEO and Co-Founder, Gareth Sheridan, will present at the 2026 Georgia Life Sciences Summit on Aug 26 as part of the CEO spotlight event. The announcement was made by the company on Aug 13, 2026.

Company

About Nutriband, Inc.

Nutriband Inc. is a pharmaceutical and healthcare company specializing in the development and commercialization of transdermal products and technologies. The primary focus of Nutriband is to improve the safety and efficacy of drug delivery systems. By leveraging transdermal adhesive materials, Nutriband Inc. offers an innovative approach to drug administration that bypasses the gastrointestinal tract and liver, enabling a more direct and controlled delivery to the bloodstream. This approach can reduce side effects and improve patient compliance. Nutriband's technologies have broader applications not only in delivering medications effectively but also in enhancing safety in medical treatments, which is critical across pharmaceutical and biotechnology industries. With its commitment to therapeutic advancements, Nutriband Inc. plays an essential role in the ongoing transformation of drug delivery systems, potentially impacting a variety of treatment areas and improving patients' experiences across different healthcare settings.

CEO Mr. Gareth Sheridan · United States · https://www.nutriband.com